$HALO
HALOZYME THERAPEUTICS, INC.

2024 Q4 Form 10-Q Financial Statement

#000115903624000050 Filed on October 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $290.1M
YoY Change 34.28%
Cost Of Revenue $49.43M
YoY Change -9.84%
Gross Profit $240.7M
YoY Change 49.28%
Gross Profit Margin 82.96%
Selling, General & Admin $41.24M
YoY Change 16.93%
% of Gross Profit 17.14%
Research & Development $18.46M
YoY Change 6.56%
% of Gross Profit 7.67%
Depreciation & Amortization $2.600M
YoY Change -3.7%
% of Gross Profit 1.08%
Operating Expenses $59.70M
YoY Change 13.52%
Operating Profit $163.2M
YoY Change 84.87%
Interest Expense $1.950M
YoY Change -56.71%
% of Operating Profit 1.19%
Other Income/Expense, Net $6.474M
YoY Change 35.27%
Pretax Income $165.1M
YoY Change 62.29%
Income Tax $28.10M
% Of Pretax Income 17.02%
Net Earnings $137.0M
YoY Change 67.42%
Net Earnings / Revenue 47.23%
Basic Earnings Per Share $1.08
Diluted Earnings Per Share $1.05
COMMON SHARES
Basic Shares Outstanding 127.2M shares 126.7M shares
Diluted Shares Outstanding 130.1M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $666.3M
YoY Change 37.87%
Cash & Equivalents $154.3M
Short-Term Investments $512.0M
Other Short-Term Assets $43.52M
YoY Change -12.09%
Inventory $131.4M
Prepaid Expenses $31.06M
Receivables $273.1M
Other Receivables $0.00
Total Short-Term Assets $1.127B
YoY Change 28.21%
LONG-TERM ASSETS
Property, Plant & Equipment $39.98M
YoY Change 6.7%
Goodwill $416.8M
YoY Change 0.0%
Intangibles $419.6M
YoY Change -14.48%
Long-Term Investments
YoY Change
Other Assets $80.15M
YoY Change 154.45%
Total Long-Term Assets $991.1M
YoY Change -2.23%
TOTAL ASSETS
Total Short-Term Assets $1.127B
Total Long-Term Assets $991.1M
Total Assets $2.118B
YoY Change 11.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.40M
YoY Change -35.82%
Accrued Expenses $96.42M
YoY Change 1.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $108.8M
YoY Change -5.53%
LONG-TERM LIABILITIES
Long-Term Debt $1.504B
YoY Change 0.44%
Other Long-Term Liabilities $40.41M
YoY Change 42.16%
Total Long-Term Liabilities $1.545B
YoY Change 1.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $108.8M
Total Long-Term Liabilities $1.545B
Total Liabilities $1.665B
YoY Change 1.33%
SHAREHOLDERS EQUITY
Retained Earnings $397.6M
YoY Change 78.88%
Common Stock $62.01M
YoY Change 141.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $452.7M
YoY Change
Total Liabilities & Shareholders Equity $2.118B
YoY Change 11.91%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $137.0M
YoY Change 67.42%
Depreciation, Depletion And Amortization $2.600M
YoY Change -3.7%
Cash From Operating Activities $115.4M
YoY Change -12.86%
INVESTING ACTIVITIES
Capital Expenditures $1.517M
YoY Change -47.69%
Acquisitions
YoY Change
Other Investing Activities -$166.0M
YoY Change 106.17%
Cash From Investing Activities -$167.5M
YoY Change 100.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.56M
YoY Change 352.71%
NET CHANGE
Cash From Operating Activities 115.4M
Cash From Investing Activities -167.5M
Cash From Financing Activities 18.56M
Net Change In Cash -33.55M
YoY Change -163.18%
FREE CASH FLOW
Cash From Operating Activities $115.4M
Capital Expenditures $1.517M
Free Cash Flow $113.9M
YoY Change -12.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001159036
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32335
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0488686
dei Entity Address Address Line1
EntityAddressAddressLine1
12390 El Camino Real
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
794-8889
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
HALO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
127227000 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154318000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118370000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
511988000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
217630000 usd
CY2024Q3 halo Accounts Receivable And Contract With Customer Asset After Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent
285743000 usd
CY2023Q4 halo Accounts Receivable And Contract With Customer Asset After Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent
234210000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
131412000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
127601000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
43515000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
48613000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1126976000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
746424000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
419592000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
472879000 usd
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Entity Registrant Name
EntityRegistrantName
HALOZYME THERAPEUTICS, INC.
CY2024Q3 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
74490000 usd
CY2023Q4 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
74944000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
80151000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
17816000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
416821000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
416821000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4386000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.45
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126969000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132896000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134083000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
129526000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135233000 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
137011000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
81837000 usd
us-gaap Net Income Loss
NetIncomeLoss
307079000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1735000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
8520000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
7000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1678000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-517000 usd
halo Business Combination Contingent Consideration Liability Gain Loss On Change In Fair Value
BusinessCombinationContingentConsiderationLiabilityGainLossOnChangeInFairValue
13200000 usd
CY2023Q4 us-gaap Assets
Assets
1733270000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12398000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11816000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
96417000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
100678000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
108815000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
112494000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1504154000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1499248000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
40406000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
37720000 usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
127183000 shares
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
452703000 usd
CY2024Q3 us-gaap Assets
Assets
2118030000 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
11952000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 usd
CY2024Q3 us-gaap Liabilities
Liabilities
1665327000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1649462000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126770000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126770000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
127000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
61886000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2409000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6939000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9278000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
397629000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
90550000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
452703000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
83808000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2118030000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1733270000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
290084000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
216033000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
717316000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
599214000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
49426000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
54823000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
117362000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
140063000 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17762000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
20341000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
53287000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
56011000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18458000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17321000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58607000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55027000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
41241000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35269000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
112086000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
111574000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
126887000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
127754000 usd
us-gaap Costs And Expenses
CostsAndExpenses
341342000 usd
us-gaap Costs And Expenses
CostsAndExpenses
362675000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
88279000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
375974000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
236539000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6474000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4786000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16499000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10957000 usd
CY2024Q3 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
18000000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2700000 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y10M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0444
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0419
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0365
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0470
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 srt Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
750000000 usd
CY2021Q4 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P3Y
CY2024Q3 us-gaap Derivative Liability Current Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q3 us-gaap Derivative Liability Noncurrent Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
127183000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
127000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
163197000 usd
CY2024Q3 halo Business Combination Contingent Consideration Liability Gain Loss On Change In Fair Value
BusinessCombinationContingentConsiderationLiabilityGainLossOnChangeInFairValue
0 usd
CY2023Q3 halo Business Combination Contingent Consideration Liability Gain Loss On Change In Fair Value
BusinessCombinationContingentConsiderationLiabilityGainLossOnChangeInFairValue
13200000 usd
halo Business Combination Contingent Consideration Liability Gain Loss On Change In Fair Value
BusinessCombinationContingentConsiderationLiabilityGainLossOnChangeInFairValue
0 usd
halo Business Combination Contingent Consideration Liability Gain Loss On Change In Fair Value
BusinessCombinationContingentConsiderationLiabilityGainLossOnChangeInFairValue
13200000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4524000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4505000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13555000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13542000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
165147000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
101760000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
378918000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
247154000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28136000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19923000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
71839000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50948000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
137011000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
81837000 usd
us-gaap Net Income Loss
NetIncomeLoss
307079000 usd
us-gaap Net Income Loss
NetIncomeLoss
196206000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.05
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.37
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126850000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131965000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
130134000 shares
us-gaap Net Income Loss
NetIncomeLoss
196206000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1272000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
706000 usd
CY2024Q3 halo Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
2000 usd
CY2023Q3 halo Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
0 usd
halo Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-5000 usd
halo Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
24000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1000 usd
CY2024Q3 halo Other Comprehensive Income Loss Cash Flow Hedge Unrealized Holding Gain Loss Before Adjustment After Tax
OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
-6919000 usd
CY2023Q3 halo Other Comprehensive Income Loss Cash Flow Hedge Unrealized Holding Gain Loss Before Adjustment After Tax
OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
3426000 usd
halo Other Comprehensive Income Loss Cash Flow Hedge Unrealized Holding Gain Loss Before Adjustment After Tax
OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
1772000 usd
halo Other Comprehensive Income Loss Cash Flow Hedge Unrealized Holding Gain Loss Before Adjustment After Tax
OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
2001000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
311000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-537000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-700000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-583000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
132140000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
84679000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
309418000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
198355000 usd
us-gaap Net Income Loss
NetIncomeLoss
307079000 usd
us-gaap Net Income Loss
NetIncomeLoss
196206000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
31923000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
26956000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7610000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8152000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
53287000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
56011000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5506000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5476000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3830000 usd
halo Business Combination Contingent Consideration Liability Gain Loss On Change In Fair Value
BusinessCombinationContingentConsiderationLiabilityGainLossOnChangeInFairValue
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2579000 usd
halo Deferred Rent Payments
DeferredRentPayments
-863000 usd
halo Deferred Rent Payments
DeferredRentPayments
0 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-15824000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-25083000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
51533000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-13546000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
59655000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
28353000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
265000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5299000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3193000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3067000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
300597000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
286217000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
596157000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
271617000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
311598000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
195697000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7644000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12698000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-292203000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-88618000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
13483000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
150083000 usd
halo Proceeds From Payments For Issuance Of Shares Share Based Payment Arrangement Including Option Exercised
ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
27554000 usd
halo Proceeds From Payments For Issuance Of Shares Share Based Payment Arrangement Including Option Exercised
ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
5499000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27554000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-158067000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35948000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
39532000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118370000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
234695000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154318000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
274227000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
320000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
533000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2622000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1211000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued1
StockIssued1
125000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
289424000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12578000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18561000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-4871000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
137011000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
452703000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
83808000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31923000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
27554000 usd
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
0 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
2339000 usd
us-gaap Net Income Loss
NetIncomeLoss
307079000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
151033000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9367000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4102000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
2842000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
81837000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
249181000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
169798000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26956000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-126000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5499000 usd
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
151301000 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
2149000 usd
us-gaap Net Income Loss
NetIncomeLoss
196206000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
249181000 usd
us-gaap Nature Of Operations
NatureOfOperations
Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the innovators of ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners’ proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ENHANZE partners’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 works by breaking down hyaluronan (“HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license our ENHANZE technology to form collaborations with biopharmaceutical companies that develop and/or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (“IV”) drugs combined with our ENHANZE technology, data has been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion-related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Takeda Pharmaceuticals International AG and Baxalta US Inc. (“Takeda”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), argenx BVBA (“argenx”), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (“ViiV”), Chugai Pharmaceutical Co., Ltd. (“Chugai”) and Acumen Pharmaceuticals, Inc. (“Acumen”). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently earn royalties from sales of eight commercial products including sales of one commercial product from each of the Takeda, Janssen and argenx collaborations and five commercial products from the Roche collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commercialized auto-injector products with Teva Pharmaceutical Industries, Ltd. (“Teva”) and Otter Pharmaceuticals, LLC (“Otter”). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (“Idorsia”).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, utilizing rHuPH20, and XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, utilizing our auto-injector technology.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to our condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries as disclosed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>
halo Royalties Received Number Of Products Sold
RoyaltiesReceivedNumberOfProductsSold
8 product
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.
us-gaap Derivatives Methods Of Accounting Hedging Derivatives
DerivativesMethodsOfAccountingHedgingDerivatives
<div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges - Currency Risks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2023, we entered into a cash flow hedging program to mitigate foreign currency exchange risk associated with forecasted royalty revenue denominated in Swiss francs. Under the program, we can hedge these forecasted royalties up to a maximum of four years into the future. We hedge these cash flow exposures to reduce the risk of our earnings and cash flows being adversely affected by fluctuations in exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge and are highly effective in offsetting changes to future cash flows on hedged transactions. Both at inception of the hedge and on an ongoing basis, we assess whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we determine a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward currency forward contract and the fair value of the hypothetical foreign currency forward contract with terms that match the critical terms of the risk being hedged. No portion of our foreign currency forward contracts were excluded from the assessment of hedge effectiveness. As of September 30, 2024, all hedges were determined to be highly effective. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets or liabilities associated with our hedging contracts are recorded at fair market value in prepaid expense and other current assets, accrued expenses, or other long-term liabilities, respectively, in our condensed consolidated balance sheets. Gains and losses related to changes in the fair market value of these hedging contracts are recorded as a component of accumulated other comprehensive income (loss) (“AOCI”) within stockholder’s equity in our condensed consolidated balance sheets and reclassified to royalty revenue in our condensed consolidated statements of income in the same period as the recognition of the underlying hedged transaction. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to royalties revenue in our condensed consolidated statements of income. Settlements from the cash flow hedge are included in operating activities on the condensed consolidated statements of cash flows. Since the fair market value of these hedging contracts is derived from current market rates, the hedging contracts are classified as derivative financial instruments. We do not use derivatives for speculative or trading purposes. As of September 30, 2024, amounts expected to be recognized as a net gain out of AOCI into our condensed consolidated statements of income during the next 12 months are not material.</span></div>
halo Revenue Remaining Performance Obligation Period Of Termination By Written Notice
RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice
P90D
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
71800000 usd
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.171
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.190
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
510562000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1486000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
60000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
511988000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
217475000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
201000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
46000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
217630000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
8 security
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
74000000.0 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
100000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
301345000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
197633000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
210643000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
19997000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
511988000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
217630000 usd
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
546701000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
241772000 usd
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1900000 usd
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6000000.0 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
290084000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
216033000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
717316000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
599214000 usd
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
57500000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
600000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
273062000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
233254000 usd
CY2024Q3 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
12681000 usd
CY2023Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
956000 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
9126000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4048000 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
9100000 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
9100000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
800000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2024Q3 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
12700000 usd
CY2024Q3 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
12681000 usd
CY2023Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
956000 usd
CY2024Q3 halo Accounts Receivable And Contract With Customer Asset Before Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent
292332000 usd
CY2023Q4 halo Accounts Receivable And Contract With Customer Asset Before Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent
240957000 usd
CY2024Q3 halo Accounts Receivable And Contract With Customer Asset Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent
6589000 usd
CY2023Q4 halo Accounts Receivable And Contract With Customer Asset Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent
6747000 usd
CY2024Q3 halo Accounts Receivable And Contract With Customer Asset After Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent
285743000 usd
CY2023Q4 halo Accounts Receivable And Contract With Customer Asset After Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent
234210000 usd
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
30579000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
23646000 usd
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
14886000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
34025000 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
143518000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
69930000 usd
CY2024Q3 halo Inventory Net Including Long Term Portion
InventoryNetIncludingLongTermPortion
188983000 usd
CY2023Q4 halo Inventory Net Including Long Term Portion
InventoryNetIncludingLongTermPortion
127601000 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
57571000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
0 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
131412000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
127601000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
31055000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36850000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
18476000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
12902000 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
57571000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
0 usd
CY2024Q3 us-gaap Other Assets
OtherAssets
16564000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
16677000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
123666000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
66429000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
80151000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
17816000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
43515000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
48613000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
63788000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
57769000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23812000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19661000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39976000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38108000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
34514000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36836000 usd
CY2024Q3 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
74490000 usd
CY2023Q4 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
74944000 usd
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2600000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1400000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1400000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7600000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8200000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4300000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4200000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
17441000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
17361000 usd
CY2024Q3 halo Accrued Outsourced Manufacturing Expenses
AccruedOutsourcedManufacturingExpenses
11179000 usd
CY2023Q4 halo Accrued Outsourced Manufacturing Expenses
AccruedOutsourcedManufacturingExpenses
12361000 usd
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
3517000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
963000 usd
CY2024Q3 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
44718000 usd
CY2023Q4 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
41932000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
29213000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
33584000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
30755000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
32197000 usd
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
136823000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
138398000 usd
CY2024Q3 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
40406000 usd
CY2023Q4 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
37720000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
96417000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
100678000 usd
CY2024Q3 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
500000 usd
CY2023Q3 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
600000 usd
halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
1700000 usd
halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
1900000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
2000000.0 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
2000000.0 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
6000000.0 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
6100000 usd
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1600000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1600000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
5100000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
5000000.0 usd
CY2023Q4 us-gaap Goodwill
Goodwill
416821000 usd
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
0 usd
CY2024Q3 us-gaap Goodwill
Goodwill
416821000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
538200000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
167308000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
370892000 usd
CY2024Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
48700000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
419592000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
17762000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
71049000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
71049000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
71049000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
71049000 usd
CY2024Q3 halo Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
68934000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
370892000 usd
CY2023Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
13500000 usd
CY2023Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
288886 shares
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1525000000 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1525000000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
20846000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
25752000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
1504154000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1499248000 usd
CY2024Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
1661475000 usd
CY2023Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
1366348000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12578000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9367000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31923000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26956000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12578000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9367000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31923000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26956000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
600000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1800000 shares
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y9M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0365
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0429
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0337
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0429
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
137011000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
81837000 usd
us-gaap Net Income Loss
NetIncomeLoss
307079000 usd
us-gaap Net Income Loss
NetIncomeLoss
196206000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126850000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131965000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126969000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132896000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
130134000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134083000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
129526000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135233000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.05
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.45
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24000000.0 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27400000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26100000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27600000 shares
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001159036-24-000050-index-headers.html Edgar Link pending
0001159036-24-000050-index.html Edgar Link pending
0001159036-24-000050.txt Edgar Link pending
0001159036-24-000050-xbrl.zip Edgar Link pending
ex31110qq32024.htm Edgar Link pending
ex31210qq32024.htm Edgar Link pending
ex3210qq32024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
halo-20240930.htm Edgar Link pending
halo-20240930.xsd Edgar Link pending
halo-20240930_g1.jpg Edgar Link pending
halo-20240930_g2.jpg Edgar Link pending
halo-20240930_g3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
halo-20240930_cal.xml Edgar Link unprocessable
halo-20240930_def.xml Edgar Link unprocessable
halo-20240930_lab.xml Edgar Link unprocessable
halo-20240930_pre.xml Edgar Link unprocessable
halo-20240930_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable